Paz and Shinfeld Dovepress to medical treatment. All patients underwent uneventful of the Transcatheter Cardiovascular Therapeutics 2010, implantations without procedure-related complications, and the 22nd Annual Scientific Symposium sponsored by the were discharged from hospital 1 to 2 days later. No major Cardiovascular Research Foundation.5 The Neovasc CSRS adverse cardiac events were reported during a follow-up was successfully implanted by the COSIRA trial principal period of 6 months, at which time most of the patients had investigator into the coronary sinus of a patient suffering improved Canadian Cardiovascular Society (CCS) scores from refractory angina pectoris. compared with baseline (3.07 versus 1.64; P , 0.0001). We hope that by improving quality of life and survival, Improvement was also seen for stress-induced ST-segment implantation of the Neovasc CSRS will prove to be the optimal depression, as well as for the extent and severity of myocar- treatment for those patients who suffer from chronic RAP. after 3 years and all CSRSs were patent and well located in 749–774. dial ischemia, as shown either by dobutamine echocardiog- raphy or by thallium single-photon emission CT. Three years follow-up of the patients has now been completed without mortality, myocardial infarctions, or device-related adverse events, while clinical improvements remain constant, as measured by CCS at 6 months of follow-up.3 Eleven patients underwent CT angiography the coronary sinus. These findings suggest that the Neovasc reducer stent may be a safe, feasible, comfortable, and effective option for many patients suffering from coronary artery disease. The Coronary Sinus Reducer for Treatment of Refractory Angina (COSIRA) study is a recent clinical multicenter trial that will reassess the efficacy of the CSRS.4 Patient enrollment began in September 2010. On September 27, 2010, the Neovasc CSRS was featured in a “live case” performed in the Antwerp Cardiovascular Institute/ZNA Middelheim in Belgium and broadcast to the main arena Disclosure The authors report no conflicts of interest in this work. References 1. Kones R. Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag. 2010;6: 2. Banai S, Ben Muvhar S, Parikh KH, et al. Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study. J Am Coll Cardiol. 2007;49:1783–1789. 3. Banai S, Schwartz M, Sievert H, et al. Long-term follow-up to evaluate the safety of the Neovasc reducer a device based therapy for chronic refractory angina. J Am Coll Cardiol. 2010;55:A98.E927. 4. CRT Online – Cardiovascular research technologies. http://www. crtonline.org/pr.aspx?PAGE_ID=7615. 5. Neovasc Reducer(TM) for Refractory Angina Featured in Live Case Session at TCT 2010 Conference. Sept 27, 2010. Available from: http://lifesciencesbc.ca/News/Member_Press_Releases/pr09271003.asp Accessed Feb 8, 2011. Vascular Health and Risk Management Publish your work in this journal Vascular Health and Risk Management is an international, peer- reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors. Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal Dovepress 136 submit your manuscript | www.dovepress.com Dovepress Vascular Health and Risk Management 2011:7